CMPX - Compass Therapeutics, Inc.
The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior to a potential BLA filing later this year. Tovecimig data from this study has also been selected for an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress in October.
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.
Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff. CMPX's lead asset, tovecimig, showed strong PFS benefit in BTC, but OS crossover contamination clouds FDA approval prospects. The Q3 2026 FDA meeting is pivotal; approval could nearly double the stock, while rejection risks 50% dilution and multi-year delays.
Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Compass Therapeutics NASDAQ: CMPX Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific antibody, after a randomized study in advanced biliary tract cancer met its primary endpoint and a key secondary endpoint.
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June.
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced a poster presentation of data from the Phase 1 study of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients with advanced malignancies treated in the post-checkpoint inhibitor setting will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, IL.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX PR Newswire
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. (“Compass” or the “Company”) (NASDAQ: CMPX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX PR Newswire
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. (“Compass” or the “Company”) (NASDAQ: CMPX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of May.
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported first quarter 2026 financial results and provided a business update.
As recently announced, tovecimig (DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement in progression-free survival (PFS) versus paclitaxel alone as well as clear signals of a survival benefit in a Phase 2/3 study of patients with biliary tract cancer (BTC); tovecimig previously met the primary endpoint of overall response rate (ORR).
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 Study in Advanced Biliary Tract Cancer Transcript
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Compass Therapeutics, Inc. (NASDAQ: CMPX). The investigation focuses on Compass Therapeutics' executive officers and whether investor losses may be recovered under federal securities laws.